EMA Authorised: Imcivree (setmelanotide) — Rhythm Pharmaceuticals Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Imcivree (setmelanotide) for obesity, including rare genetic disorders of the melanocortin-4 receptor pathway, under Rh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lepr Deficiency Obesity
• Mc4r Deficiency Obesity
• Pcsk1 Deficiency Obesity
• Pomc Deficiency Obesity

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

Status: Authorised. Therapeutic area: Obesity. MAH: Rhythm Pharmaceuticals Netherlands B.V.. Decision date: 11/12/2025. Orphan medicine